AZD3293

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
02420142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
The relative bioavailability of lanabecestat administered as 2 tablet formulations versus an oral solution was investigated. This… (More)
Is this relevant?
2017
2017
AZD3293 (LY3314814) is a promising new potentially disease-modifying BACE1 (β-secretase) inhibitor in Phase III clinical… (More)
Is this relevant?
2017
2017
Lanabecestat (AZD3293; LY3314814) is an orally active potent inhibitor of human β-secretase 1 in clinical development for the… (More)
Is this relevant?
2017
2017
AIM AZD3293 is a novel BACE1 inhibitor in Phase III development for Alzheimer's disease. Sensitive and robust bioanalytical… (More)
Is this relevant?
Review
2017
Review
2017
Alzheimer’s disease (AD) is a major form of senile dementia, characterized by progressive memory and neuronal loss combined with… (More)
  • figure 1
Is this relevant?
2017
2017
The β-secretase (BACE1) initiates the generation of toxic amyloid-β peptide (Aβ) from amyloid-β precursor protein (APP), which… (More)
Is this relevant?
2016
2016
A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of… (More)
  • table 1
  • table 2
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
BACKGROUND AZD3293 (also known as LY3314814) is a novel, potent, non-selective BACE1/BACE2 inhibitor currently in Phase 3… (More)
Is this relevant?
2016
2016
but are looking for efficacy in slightly different patient populations. In 2014 AstraZeneca started enrolling 2,200 patients into… (More)
Is this relevant?
2014
2014
Eli Lilly and Company and AstraZeneca have entered into a 50:50 partnership to develop AZD3293, AstraZeneca’s β-secretase (BACE… (More)
Is this relevant?